Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its vaginal derma product (the "Product").The results of the Trial demonstrate that Innocan's Product, which contains cannabinoids, phytoestrogens, hyaluronic acid, and probiotics, effectively reduced the symptoms, and improved overall vaginal health.The 56-day Trial...
2023-03-23 4:00 AM EDT
Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.Innocan CEO, Iris Bincovich, stated, "We are excited to announce the appointment of a dedicated...
2023-03-17 3:30 AM EDT
Innocan Pharma Announces First Patent Grant in the United States
This is the first fully granted patent of Innocan in the United StatesThe Patent covers Innocan's proprietary cannabis-based pain relief topical This serves as an indication of Innocan's growing intellectual property portfolioHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 12, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property (IP) portfolio, is pleased to announce...
2023-03-12 11:18 AM EDT
Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial
"Lady", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune mediated polyarthritis.Lady was treated with Glycoflex, steroids, and hydrotherapy, but still suffered pain and had difficulty walking more than a few steps.Lady was administered Innocan's liposomal CBD injection and experienced significant improvement, which lasted more than five weeks, indicating the long-acting nature of the liposomal CBD formulation.Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 21, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF)...
2023-02-21 5:22 AM EST
Innocan Pharma Provides Annual "State of the Business" Update
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 16, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report an annual "State of the Business" update, including with respect to the company's advancements in Research, Intellectual Property and Commercialization, alongside announcing the closing of a non-brokered private placement offering of 1,982,000 units...
2023-02-16 4:00 PM EST
Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's commercialization of IP in the veterinary field. The principal of Benitz Consulting is Dr. Antonio Benitz, ex Novartis Animal Health and Pharmacia Animal...
2022-12-02 4:00 PM EST
Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and are confident in our long-term outlook" says Iris...
2022-11-29 3:00 AM EST
Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Givi Topchishvili will join the advisory team to support Innocan's goals to expand...
2022-11-18 2:30 AM EST
Innocan Pharma Goes Live with Priority(TM) ERP System
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 9, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the successful implementation of Priority Software's Priority™ Enterprise Resource Planning (ERP). The new Priority™ ERP system includes financial, logistics, and revenue analysis modules. The new system will optimize numerous financial and procurement processes...
2022-11-09 4:00 PM EST
Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce its participation in a webinar titled "Investor Day: Companies Disrupting The World We Live In", co-hosted by IR Labs Inc. ("irlabs") and the NEO Exchange. The webinar will take place on Wednesday, November 2,...
2022-10-25 3:00 AM EDT
Innocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 13, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabinoids (CBD) is pleased to announce that it will be participating in the Luxury Meets CBD Conference (LMCC) Fall 2022, on October 20th and 21st in New York where Innocan will showcase its patent pending topicals and premium CBD Derma cosmetic...
2022-10-13 9:24 AM EDT
Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabinoids science, is pleased to report an additional milestone with respect to Innocan patent application: PCT application WO2021/240505 that claims Cannabinoids Based Topical Compositions for Treatment of Psoriasis of the Scalp, reached national phase. Entering the national phase is one of the...
2022-10-06 9:35 AM EDT
Innocan Pharma Provides an Operational Update
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 21, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, is pleased to provide the following operational update on its key lines of business:Recent development: We are happy to announce that the PCT title as " CANNABIDIOL-CONTAINING COMPOSITIONS AND USES THEREOF " was entered national phase in US and...
2022-09-21 7:05 AM EDT
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsyThe dog was frequently hospitalized to stop seizure clusters Following treatment using Innocan's LPT (CBD Loaded Liposome Platform), seizures stopped for 9.5 weeksHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 9, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce additional positive results in a new preclinical trial involving a...
2022-09-09 3:00 AM EDT
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, today announced that Iris Bincovich CEO of Innocan Pharma, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.Mrs. Iris Bincovich's...
2022-09-06 3:00 AM EDT
Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June 30, 2022. Second Quarter 2022 Financial and Operating Highlights (unaudited):Cash balance at end of Q2-22 - USD 7.7M, in Q2-21 - USD 4.6M, an increase of approximately of 70% from the corresponding quarter.Revenues in Q2-22 - USD 415 thousand compared to Q2-21 - USD...
2022-08-30 3:00 AM EDT
Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology
6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injectionPain and well-being scores improved following treatmentHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform.Six dogs suffering from osteoarthritis and lameness that were treated with oral analgesics but were...
2022-08-17 3:00 AM EDT
Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform
First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technologyThis is compared to 6.5-20% bioavailability in humans when administered orallyHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce results that approached 100% bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system in a clinical study conducted on dogs suffering from pain...
2022-08-11 3:00 AM EDT
Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", claiming priority from an earlier US provisional patent application. The composition developed by Innocan research and development and disclosed in the current PCT can be used to treat and prevent hair loss and is applied topically...
2022-08-05 3:00 AM EDT
Innocan Pharma Files PCT Patent Application for Diabetic Symptoms
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of diabetic symptoms", claiming priority from an earlier US provisional patent application. This application contributes to Innocan's continued expansion of its health and wellness intellectual property portfolio of 14 patent families. The application will ultimately result in more comprehensive...
2022-07-29 3:00 AM EDT